The strong buying from active quant (RenTech) and asset manager (Nuveen) funds signals conviction in Esperion's near-term prospects, but the 45-day 13F lag means positions may already be stale. Watch for Q4 2025 13F filings to see if these adds were maintained or reversed, and monitor upcoming earnings for revenue trajectory on NEXLETOL/NEXLIZET.
ESPR drugs
ESPR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jun 11 $3.15entry
- T+1 · 5mo ago 0.00%α −0.54% · $3.15
- T+5 · 5mo ago +0.63%α +0.20% · $3.17
- T+20 · 4mo ago +1.27%α −0.62% · $3.19
- T+60 · due 2mo ago Pending
How similar events traded
Executive Summary
Four institutional investors added $22.0M in ESPR positions during Q3 2025, led by Morgan Stanley and Nuveen doubling their stakes, while Citadel and BofA trimmed $1.7M. The cluster is mixed but dominated by active buying from quant and asset-manager funds, suggesting a shared thesis around Esperion's commercial execution or pipeline catalysts, though the 45-day reporting lag means positions may have shifted since quarter-end.
Key Financial Metrics
Institutional Positions
Net institutional flow: $20.3M
▲ Buyers (4)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | DOUBLED | +284.2% | $10.7M | $9.7M |
| Nuveen | DOUBLED | +778.1% | $9.8M | $9.4M |
| RenTech | DOUBLED | +164.7% | $2.1M | $1.8M |
| Invesco | ADD | +25.5% | $1.6M | $1.2M |
▼ Sellers (2)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Citadel | TRIM | -34.3% | $2.3M | $1.8M |
| BofA | TRIM | -63.6% | $823.0K | -$15.8K |
Key Facts
- 4 buyers added $22.0M in net new positions; 2 sellers reduced by $1.7M
- Morgan Stanley doubled its stake (+284.2%) to $10.7M; Nuveen nearly 8x'd to $9.8M
- RenTech doubled (+164.7%) to $2.1M; Invesco added 25.5% to $1.6M
- Citadel trimmed 34.3% but still holds $4.1M; BofA cut 63.6% to $807K
- Active managers (Nuveen, RenTech) dominate the buying side; passive funds (Morgan Stanley, Invesco) also added
Financial Impact
4 institutions accumulated $22.0M in new positions while 2 reduced holdings by $1.7M, net institutional inflow of ~$20.3M
Risk Factors
- 13F data is 45+ days stale; positions may have been unwound since quarter-end
- Analyst consensus is 0% bullish (8 Hold, 3 Sell/Strong Sell), institutional buying is contrarian to Street sentiment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-ESPR-2025-Q3 |
Track record
21 reports on ESPR
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
- Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
- Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
- Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
- Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Viewing Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers